Bakhos A. Tannous

Harvard University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

55h-index13.5kcitations238works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

bioluminescence and chemiluminescence research(35), Extracellular vesicles in disease(34), MicroRNA in disease regulation(25), Cancer-related molecular mechanisms research(25), Chemical Reactions and Isotopes(25)

Publications237 total

Challenges to determine synergistic drug interactions in mice
Nature Communications·2025· 1 citedOpen Access
Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy
European Journal of Pharmaceutical Sciences·2025Open Access
Abstract LB191: The natural compound KH617 targets pediatric and adult high-grade gliomas
Cancer Research·2025
Rabies virus-mimicking liposomes for targeted gene therapy in Alzheimer’s disease
International Journal of Pharmaceutics·2024· 2 cited
Arming AAV9 with a Single-Chain Fragment Variable Antibody Against PD-1 for Systemic Glioblastoma Therapy
Molecular Neurobiology·2024· 3 citedOpen Access
Abstract B038: Accurate quantitative profiling of rna modifications and their associations with glioblastoma
Cancer Research·2024
Glioblastoma extracellular vesicles modulate immune PD-L1 expression in accessory macrophages upon radiotherapy
iScience·2024· 13 citedOpen Access
Design and Implementation of a Leadership Development Program for Early-Stage Investigators: Initial Results
Journal of Continuing Education in the Health Professions·2023· 1 citedOpen Access
Activation of cannabinoid type 1 receptor (CB1) modulates oligodendroglial process branching complexity in rat hippocampal cultures stimulated by olfactory ensheathing glia-conditioned medium
Frontiers in Cellular Neuroscience·2023· 4 citedOpen Access
Supplementary Figure 2 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Supplementary Figure 2 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Supplementary Figure 3 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Supplementary Figure 1 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Table S1 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Table S2 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Supplementary Figure 6 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Data from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Supplementary Figure 5 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Table S2 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
Supplementary Figure 7 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Thomas Würdinger(15), David P. Noske(11), Johanna M. Niers(8), Xandra O. Breakefield(7), Ralph Weissleder(7), Christian E. Badr(7), R. Jonas A. Nilsson(6), W. Peter Vandertop(6), Casey A. Maguire(5), Jihane Tannous(5), Pieter Wesseling(5), Song Fan(4), Nik Sol(4), Pepijn Schellen(4), Laurine E. Wedekind(4), Philip C. De Witt Hamer(4), Xandra O. Breakefield(4), Tonny Lagerweij(4), Tian Tian(3), Jun Gao(3)